Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Titel:
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Auteur:
Stuart, Arabella S V Shaw, Robert H Liu, Xinxue Greenland, Melanie Aley, Parvinder K Andrews, Nick J Cameron, J C Charlton, Sue Clutterbuck, Elizabeth A Collins, Andrea M Darton, Tom Dinesh, Tanya Duncan, Christopher J A England, Anna Faust, Saul N Ferreira, Daniela M Finn, Adam Goodman, Anna L Green, Christopher A Hallis, Bassam Heath, Paul T Hill, Helen Horsington, Bryn M Lambe, Teresa Lazarus, Rajeka Libri, Vincenzo Lillie, Patrick J Mujadidi, Yama F Payne, Ruth Plested, Emma L Provstgaard-Morys, Samuel Ramasamy, Maheshi N Ramsay, Mary Read, Robert C Robinson, Hannah Screaton, Gavin R Singh, Nisha Turner, David P J Turner, Paul J Vichos, Iason White, Rachel Nguyen-Van-Tam, Jonathan S Snape, Matthew D